NO20082023L - Pyrrolotriazin kinaseinhibitorer - Google Patents
Pyrrolotriazin kinaseinhibitorerInfo
- Publication number
- NO20082023L NO20082023L NO20082023A NO20082023A NO20082023L NO 20082023 L NO20082023 L NO 20082023L NO 20082023 A NO20082023 A NO 20082023A NO 20082023 A NO20082023 A NO 20082023A NO 20082023 L NO20082023 L NO 20082023L
- Authority
- NO
- Norway
- Prior art keywords
- kinase inhibitors
- formula
- pyrrolotriazine kinase
- pyrrolotriazine
- compounds
- Prior art date
Links
- SUPXSFXAMJPEPH-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]triazine Chemical compound N1=NC=C2NC=CC2=N1 SUPXSFXAMJPEPH-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 abstract 1
- 101150111783 NTRK1 gene Proteins 0.000 abstract 1
- 101150117329 NTRK3 gene Proteins 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73826905P | 2005-11-18 | 2005-11-18 | |
| US11/560,378 US7514435B2 (en) | 2005-11-18 | 2006-11-16 | Pyrrolotriazine kinase inhibitors |
| PCT/US2006/044756 WO2007061882A2 (en) | 2005-11-18 | 2006-11-17 | Pyrrolotriazine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20082023L true NO20082023L (no) | 2008-08-05 |
Family
ID=38051768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082023A NO20082023L (no) | 2005-11-18 | 2008-04-29 | Pyrrolotriazin kinaseinhibitorer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7514435B2 (de) |
| EP (1) | EP1948664B1 (de) |
| JP (1) | JP5095626B2 (de) |
| KR (1) | KR101392678B1 (de) |
| CN (1) | CN101365701B (de) |
| AT (1) | ATE512151T1 (de) |
| AU (1) | AU2006318682B2 (de) |
| NO (1) | NO20082023L (de) |
| WO (1) | WO2007061882A2 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| PE20070855A1 (es) * | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| KR101461680B1 (ko) | 2005-12-02 | 2014-11-19 | 바이엘 헬스케어 엘엘씨 | 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체 |
| US8124759B2 (en) * | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
| MX2010000123A (es) * | 2007-07-03 | 2010-04-07 | Sanofi Aventis | Un procedimiento para el acoplamiento catalizado por paladio de alquinos terminales con tosilatos de heteroarilo y bencenosulfonatos de heteroarilo. |
| MX2010003269A (es) | 2007-09-25 | 2010-08-02 | Bayer Healthcare Llc | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. |
| RU2461551C2 (ru) | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль |
| EP2344504B1 (de) * | 2008-10-08 | 2014-06-04 | Bristol-Myers Squibb Company | Pyrrolotriazin-kinaseinhibitoren |
| EP2376491B1 (de) | 2008-12-19 | 2015-03-04 | Cephalon, Inc. | Pyrrolotriazine als alk- und jak2-inhibitoren |
| WO2010126960A1 (en) * | 2009-04-29 | 2010-11-04 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| JP5752232B2 (ja) * | 2010-03-31 | 2015-07-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物 |
| KR102001364B1 (ko) * | 2011-05-13 | 2019-07-22 | 어레이 바이오파마 인크. | Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물 |
| JP5955953B2 (ja) | 2011-07-01 | 2016-07-20 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Ａｌｋ１阻害剤としてのヒドロキシメチルアリール−置換ピロロトリアジン |
| JP6047582B2 (ja) | 2011-12-15 | 2016-12-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換ベンゾチエニル−ピロロトリアジンおよび癌の処置におけるその使用 |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| CA2865021C (en) | 2012-02-23 | 2020-06-30 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
| CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| WO2014053968A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| RU2664541C2 (ru) | 2012-11-13 | 2018-08-20 | Эррэй Биофарма Инк. | Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли |
| US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
| UA116455C2 (uk) | 2012-11-13 | 2018-03-26 | Еррей Біофарма Інк. | Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2015054358A1 (en) | 2013-10-11 | 2015-04-16 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| MY191956A (en) | 2014-05-15 | 2022-07-20 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
| CN104151276A (zh) * | 2014-06-30 | 2014-11-19 | 北京万全德众医药生物技术有限公司 | 一种盐酸决奈达隆代谢杂质的制备方法 |
| EP3209665B1 (de) | 2014-10-22 | 2019-08-14 | Bristol-Myers Squibb Company | Substituierte pyrrolotriazinaminverbindungen als pi3k-hemmer |
| ES2807785T3 (es) | 2014-10-22 | 2021-02-24 | Bristol Myers Squibb Co | Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k |
| CN114456176B (zh) | 2016-03-28 | 2024-08-30 | 因赛特公司 | 作为tam抑制剂的吡咯并三嗪化合物 |
| CN112225723B (zh) * | 2020-12-16 | 2021-03-30 | 北京华氏开元医药科技有限公司 | 一种吲哚类衍生物、制备方法及应用 |
| JP7840066B2 (ja) * | 2021-05-03 | 2026-04-03 | ジェービーケーラボ カンパニー リミテッド | ２，６－ジクロロ－４－（４－（４－ヒドロキシシクロヘキシルアミノ）－７ｈ－ピロロ［２，３－ｄ］ピリミジン－５－イル）フェノールを活性成分として含有する、がんを予防、緩和、または処置するための医薬組成物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199900389T2 (xx) | 1996-08-28 | 2000-06-21 | Pfizer Inc. | �kame edilmi� 6,5-hetero-bisiklik t�revleri. |
| CZ303660B6 (cs) * | 1999-05-21 | 2013-02-13 | Bristol-Myers Squibb Company | Pyrrolotriazin a farmaceutický prostredek s jeho obsahem |
| US6787545B1 (en) | 1999-08-23 | 2004-09-07 | Shiongi & Co., Ltd. | Pyrrolotriazine derivatives having spla2-inhibitory activities |
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| KR100847605B1 (ko) | 2000-11-17 | 2008-07-21 | 브리스톨-마이어스스퀴브컴파니 | ｐ38 키나제 관련 질병의 치료 방법 및 키나제 억제제로서유용한 피롤로트리아진 화합물 |
| ES2275021T3 (es) | 2001-09-27 | 2007-06-01 | Smithkline Beecham Corporation | Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico. |
| TW200300350A (en) | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
| JP2005529890A (ja) * | 2002-04-23 | 2005-10-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物 |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US6933386B2 (en) | 2002-07-19 | 2005-08-23 | Bristol Myers Squibb Company | Process for preparing certain pyrrolotriazine compounds |
| WO2004013145A1 (en) | 2002-08-02 | 2004-02-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| UY28931A1 (es) * | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7102003B2 (en) | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| JP5116687B2 (ja) * | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
-
2006
- 2006-11-16 US US11/560,378 patent/US7514435B2/en active Active
- 2006-11-17 AT AT06837967T patent/ATE512151T1/de not_active IP Right Cessation
- 2006-11-17 CN CN2006800513398A patent/CN101365701B/zh not_active Expired - Fee Related
- 2006-11-17 WO PCT/US2006/044756 patent/WO2007061882A2/en not_active Ceased
- 2006-11-17 AU AU2006318682A patent/AU2006318682B2/en not_active Ceased
- 2006-11-17 EP EP06837967A patent/EP1948664B1/de active Active
- 2006-11-17 JP JP2008541376A patent/JP5095626B2/ja not_active Expired - Fee Related
-
2008
- 2008-04-29 NO NO20082023A patent/NO20082023L/no not_active Application Discontinuation
- 2008-06-17 KR KR1020087014666A patent/KR101392678B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007061882A2 (en) | 2007-05-31 |
| AU2006318682B2 (en) | 2012-04-05 |
| EP1948664B1 (de) | 2011-06-08 |
| CN101365701B (zh) | 2011-11-30 |
| ATE512151T1 (de) | 2011-06-15 |
| AU2006318682A1 (en) | 2007-05-31 |
| JP2009515995A (ja) | 2009-04-16 |
| KR101392678B1 (ko) | 2014-05-07 |
| KR20080079262A (ko) | 2008-08-29 |
| EP1948664A2 (de) | 2008-07-30 |
| JP5095626B2 (ja) | 2012-12-12 |
| CN101365701A (zh) | 2009-02-11 |
| WO2007061882A3 (en) | 2007-08-16 |
| US7514435B2 (en) | 2009-04-07 |
| US20070149534A1 (en) | 2007-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE512151T1 (de) | Pyrrolotriazin-kinaseinhibitoren | |
| NO20091374L (no) | Pyrrolotriazin kinase inhibitorer | |
| LTPA2021516I1 (de) | ||
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| NO20081160L (no) | Benzimidazoltiofen forbindelser | |
| NO20073859L (no) | Pyrrolopyrazoler, potente kinaseinhibitorer | |
| NO20062188L (no) | Pyrazolderivater som inhibitorer av reseptor tyrosin kinaser | |
| NO20081454L (no) | Met-kinaseinhibitorer | |
| MY151455A (en) | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors | |
| NO20070323L (no) | Organiske forbindelser | |
| NO20074275L (no) | 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister | |
| NO20081844L (no) | Terapeutiske forbindelser | |
| DK1791830T3 (da) | Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer | |
| NO20083246L (no) | Nye benzimidazolderivater som vanilloid-reseptor 1 (VRL) inhibitorer | |
| DK1456212T3 (da) | 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse | |
| EA200801199A1 (ru) | Ингибиторы киназы | |
| NO20070550L (no) | Fremgangsmate for fremstilling av pyrrolotriazinforbindelser | |
| NO20080553L (no) | Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander | |
| ECSP077993A (es) | Intermedios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina cinasa y metodos relacionados de sintesis | |
| ATE548364T1 (de) | Aminopyrazolkinasehemmer | |
| EA200602081A1 (ru) | Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7 | |
| NO20064410L (no) | Fremgangsmate for fremstilling av tryptaseinhibitorer | |
| UA90254C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| UA92047C2 (uk) | Карбоніламінопіролпіразоли - потужні інгібітори кінази | |
| NO20082412L (no) | Kinaseinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |